Drug intelligence / Profile preview

fulvestrant + ipatasertib

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

Fulvestrant + ipatasertib is a combination therapy that pairs fulvestrant, an estrogen receptor antagonist, with ipatasertib, an AKT inhibitor. This combination has shown significant efficacy in treating estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer in patients who have progressed on prior aromatase inhibitor and CDK4/6 inhibitor treatment. The combination works by simultaneously blocking estrogen receptor signaling (fulvestrant) and inhibiting the AKT pathway (ipatasertib), which is often activated in resistant breast cancers.

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)ER (Estrogen receptor)

Beyond the preview

Go deeper on fulvestrant + ipatasertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + ipatasertib.

Explore the full profile